Targeting a new protein to treat acute myeloid leukemia
PolQ as a novel therapeutic target in AML
This study is looking at a protein called Polθ that helps cancer cells survive in acute myeloid leukemia (AML), and it's trying to find new treatments that block this protein to help patients live longer and healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10757755 on NIH RePORTER |
What this research studies
This research focuses on acute myeloid leukemia (AML), a common and aggressive type of leukemia in adults. It investigates the role of a protein called Polθ, which helps AML cells survive by repairing DNA damage. The study aims to develop new therapies that inhibit Polθ, potentially leading to better treatment outcomes for patients with AML. By understanding how AML cells utilize this protein, researchers hope to create targeted treatments that could improve survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia, particularly those with specific genetic mutations.
Not a fit: Patients with other types of leukemia or those who do not have the specific genetic markers associated with AML may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting DNA repair mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Skorski, Tomasz — Temple Univ of the Commonwealth
- Study coordinator: Skorski, Tomasz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.